首页365bet娱乐官网网址365bet国际娱乐城365bet体育在线官电子期刊下载专区广告合作征稿启事留言板
位置:首页 >> 电子期刊 >> 正文
ⅠB2和ⅡA2期子宫颈癌术前近距离放疗联合同步化疗的近期疗效及安全性
作者:陈悦  肖苏  潘伟 
单位:鄂东医疗集团黄石市中心医院  湖北理工学院附属医院妇产科  湖北 黄石 435000 
365bet娱乐官网网址关键词:宫颈肿瘤/放射疗法 宫颈肿瘤/药物疗法 宫颈肿瘤/外科学 近距离放射疗法 肿瘤分期 化学疗法 辅助 安全 治疗结果 
DOI:R737.33;R730.55
出版年,卷(期):页码:2018,33(2):146-149
摘要:

目的 探讨ⅠB2和ⅡA2期子宫颈癌术前近距离放疗联合同步化疗的近期疗效及安全性。方法 收集120例ⅠB2和ⅡA2期子宫颈癌患者,按照随机数字表法均分为放疗联合化疗组、化疗组和放疗组。放疗联合化疗组行术前近距离放疗(行腔内后装放疗,192Ir为放射源,5~9 Gy/次,2~3次,总剂量10~27 Gy。)联合同步化疗[顺铂(250~350 mg/m 2)联合紫杉醇(130~170 mg/m 2)的新辅助化疗,全身静脉化疗2 d后,通过微量泵持续静脉注入化疗],化疗组仅行新辅助化疗,放疗组仅行术前近距离放疗。比较三组近期疗效、临床症状改善情况以及治疗后不良反应情况。结果 放疗联合化疗组近期总有效率为90.0%,高于化疗组的70.0%和放疗组的65.0%,组间比较差异具有统计学意义(P<0.05)。三组治疗后阴道排液和出血均有明显改善,组间比较差异无统计学意义(P>0.05)。治疗后,放疗联合化疗组Ⅰ~Ⅱ级骨髓抑制和消化道反应发生率分别为20.0%(8/40)和40.0%(16/40),化疗组为5.0%(2/40)和22.5%(9/40),放疗组为5.0%(2/40)和20.0%(8/40),组间比较差异均具有统计学意义(均P<0.05)。三组均无Ⅲ~Ⅳ级不良反应发生。结论 术前近距离放疗联合同步化疗治疗ⅠB2和ⅡA2期子宫颈癌患者能有效改善临床症状,近期疗效较好,安全性较高。

Objective To investigate the short-term efficacy and safety of preoperative brachytherapy combined with concurrent chemotherapy for stageⅠB2 and ⅡA2 cervical cancer. Methods One-hundred-and-twenty cases of stage ⅠB2 and ⅡA2 cervical cancer were enrolled and divided into brachytherapy combined with chemotherapy group, chemotherapy group and brachytherapy group, according to random number table method. The brachytherapy combined with chemotherapy group was treated with preoperative brachytherapy (intracavitary afterloading radiotherapy, 192Ir radiation source, 5-9 Gy/cycle, 2-3 cycles, a total dose of 10-27 Gy) and concurrent neoadjuvant chemotherapy (250-350 mg/m2 cisplatin, 130-170 mg/m2 paclitaxel). The chemotherapy was administered systemically for two days and then followed by continuous intravenous injection with trace pump. The chemotherapy group was treated with chemotherapy only and the brachytherapy was treated with brachytherapy only. The short-term efficacy, clinical improvement and the adverse reactions were compared among the three groups. Results The total efficiency was 90.0% in the brachytherapy combined with chemotherapy group, which was higher than that in the chemotherapy group (70.0%) or the brachytherapy group (65.0%), with a statistical significance (P<0.05). Nevertheless, vaginal discharge and bleeding were similarly improved in all three groups (P>0.05). After treatment, the incidences of grade Ⅰ-Ⅱ bone marrow suppression and gastrointestinal reactions were 20.0% (8/40) and 40.0% (16/40) in the brachytherapy combined with chemotherapy group, 5.0% (2/40) and 22.5% (9/40) in the chemotherapy group, and 5.0% (2/40) and 20.0% (8/40) in the brachytherapy group. The differences among the three groups were statistically significant (both P<0.05). No occurrence of grade Ⅲ-Ⅳ adverse effect was reported in all cases. Conclusions Preoperative brachytherapy combined with chemotherapy can significantly relieve the clinical symptoms of stageⅠB2 and ⅡA2 cervical cancer patients, with good short-term clinical efficacy and high safety.

文章下载】【加入收藏

浙ICP备18004413号

技术服务qq:1507079184(投稿系统问题可找我)

编辑部地址:浙江省杭州市上城区解放路88号(浙医二院内)

电话:0571-87783654 邮编:310009 E-mail:shyzhl@zju.edu.cn

期刊介绍 使用帮助 | 365bet体育在线官 | 留言板